On the REPROCELL blog
Latest
Discover how integrating AI with ex vivo human tissue data is revolutionizing drug discovery by enhancing predictive accuracy and bridging the gap between preclinical and clinical research.
12 February 2026
The Critical Role of Central Laboratory Services in Regulatory Compliance and Data Integrity
Explore the critical role of Central Laboratory Services in ensuring data integrity and regulatory compliance in drug development. Learn how CLS supports reliable, reproducible, and auditable data.
27 January 2026
Modeling Fibrosis Progression Ex Vivo: Opportunities for Anti-Fibrotic Drug Screening
Explore the benefits of ex vivo human tissue models for fibrosis research and anti-fibrotic drug screening, offering a more accurate alternative to conventional preclinical methods.
15 January 2026
OpenCRISPR-1: The First AI-Designed CRISPR Editor for High-Precision Gene & Cell Therapy
Discover OpenCRISPR-1 — the first fully AI-designed CRISPR–Cas editor. Built by generative large language model, it enables high-efficiency, high-specificity genome and base editing in human cells. Ideal for cell therapy, stem-cell research, and advanced gene-editing workflows.
16 December 2025